Select Page

Are You CovidMune?™

Hydroxychloroquine and NLRP3

Lysosomotropic drugs enhance pro-inflammatory responses to IL-1β in macrophages by inhibiting internalization of the IL-1 receptor.
Lübow C, Bockstiegel J, Weindl G.
Biochem Pharmacol. 2020 Feb 20;175:113864. doi: 10.1016/j.bcp.2020.113864. [Epub ahead of print]

Hydroxychloroquine inhibits IL-1β production from amyloid-stimulated human neutrophils.
Fujita Y, Matsuoka N, Temmoku J, Furuya MY, Asano T, Sato S, Kobayashi H, Watanabe H, Suzuki E, Urano T, Kozuru H, Yatsuhashi H, Koga T, Kawakami A, Migita K.
Arthritis Res Ther. 2019 Nov 27;21(1):250. doi: 10.1186/s13075-019-2040-6.

Prevention of crystalline silica-induced inflammation by the anti-malarial hydroxychloroquine.
Burmeister R, Rhoderick JF, Holian A.
Inhal Toxicol. 2019 Jun;31(7):274-284. doi: 10.1080/08958378.2019.1668091. Epub 2019 Sep 26.

Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-κB signaling and NLRP3 inflammasome activation by exosomes in rats.
Bai L, Li J, Li H, Song J, Zhou Y, Lu R, Liu B, Pang Y, Zhang P, Chen J, Liu X, Wu J, Liang C, Zhou J.
Biochem Pharmacol. 2019 Nov;169:113619. doi: 10.1016/j.bcp.2019.08.021. Epub 2019 Aug 26.

Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation.
Tang TT, Lv LL, Pan MM, Wen Y, Wang B, Li ZL, Wu M, Wang FM, Crowley SD, Liu BC.
Cell Death Dis. 2018 Mar 2;9(3):351. doi: 10.1038/s41419-018-0378-3.

Pro-inflammatory Ca++-activated K+ channels are inhibited by hydroxychloroquine.
Eugenia Schroeder M, Russo S, Costa C, Hori J, Tiscornia I, Bollati-Fogolín M, Zamboni DS, Ferreira G, Cairoli E, Hill M.
Sci Rep. 2017 May 15;7(1):1892. doi: 10.1038/s41598-017-01836-8.

Chorea in a patient with cryopyrin-associated periodic syndrome.
Schwarzbach CJ, Schmitt WH, Szabo K, Bäzner H, Hennerici MG, Blahak C.
Neurology. 2016 Jan 19;86(3):241-4. doi: 10.1212/WNL.0000000000002300. Epub 2015 Dec 18.

Anti-inflammatory therapies for cardiovascular disease.
Ridker PM, Lüscher TF.
Eur Heart J. 2014 Jul 14;35(27):1782-91. doi: 10.1093/eurheartj/ehu203. Epub 2014 May 26. Review.